The original manufacturer of voriconazole injection is Pfizer, and the product name is vfend (Voriconazole) 200mg. It is a freeze-dried powder injection for intravenous injection. The excipient used is betadex sulfobutyl ether sodium(SBECD).
Voriconazole is an antifungal drug to kill or prevent the growth of the fungus that causes the infection. It is used to treat the following types of patients (adults and children over 2 years old):
●Invasive aspergillosis (a fungal infection caused by Aspergillus).
●Candidiasis (another fungal infection caused by Candida) in patients with non-neutropenia (abnormally low white blood cell count).
●Severely invasive Candida fungus is resistant to fluconazole (another antifungal drug).
●Severe fungal infection caused by Scedosporium sp or Fusarium (two different fungal species). It is suitable for patients with worsening condition and even possible life-threatening fungal infections. It can also be used to prevent fungal infections in high-risk bone marrow transplant recipients.
In vfend injection:
The molar ratio of voriconazole and sulfobutyl beta cyclodextrin is 1:2.6, and the weight ratio is 1:16. 200 mg Voriconazole injection freeze-dried powder injection is equipped with 3200 mg sulfobutyl beta cyclodextrin sodium.
The patent validity period of voriconazole for injection is: 2019 (US 09/402,289)
Shandong Binzhou Zhiyuan Biological Technology Co., Ltd. is committed to the professional production of pharmaceutical excipients: sulfobutyl beta cyclodextrin sodium, which has been filed with CDE, and other main products are hydroxypropyl beta cyclodextrin (HPBCD), betadex sulfobutyl ether sodium (SBECD) and methyl beta cyclodextrin (MBECD). It is a domestic manufacturer of cyclodextrin derivatives with various types and complete specifications.